Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Recruiting · NCT04746209 · Registry updated 2021-09-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT | B-cell acute lymphoblastic leukemia, B-cell childhood acute lymphoblastic leukemia, B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 2 | 2021-09-17 | NCT04746209 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Amgen | 180 |
| Medical College of Wisconsin | 201 |
| University of Wisconsin, Madison | 265 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital of Wisconsin | Milwaukee | United States | 87 |